JP2004515208A5 - - Google Patents

Info

Publication number

JP2004515208A5

JP2004515208A5 JP2001570836A JP2001570836A JP2004515208A5 JP 2004515208 A5 JP2004515208 A5 JP 2004515208A5 JP 2001570836 A JP2001570836 A JP 2001570836A JP 2001570836 A JP2001570836 A JP 2001570836A JP 2004515208 A5 JP2004515208 A5 JP 2004515208A5

Authority

JP

Japan

Prior art keywords

oligonucleotide

bound

analyte

specific binding

nanoparticles

Prior art date

2001-03-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 108091034117 Oligonucleotide Proteins 0.000 claims 447
• 239000002105 nanoparticle Substances 0.000 claims 213
• 230000000295 complement effect Effects 0.000 claims 176
• 230000009870 specific binding Effects 0.000 claims 138
• 239000012491 analyte Substances 0.000 claims 131
• 238000009396 hybridization Methods 0.000 claims 86
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 79
• 108020004707 nucleic acids Proteins 0.000 claims 79
• 150000007523 nucleic acids Chemical class 0.000 claims 79
• 102000039446 nucleic acids Human genes 0.000 claims 79
• 239000000523 sample Substances 0.000 claims 78
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 76
• 238000000034 method Methods 0.000 claims 55
• 239000011616 biotin Substances 0.000 claims 38
• 229960002685 biotin Drugs 0.000 claims 38
• 235000020958 biotin Nutrition 0.000 claims 38
• 108090001008 Avidin Proteins 0.000 claims 28
• 108010090804 Streptavidin Proteins 0.000 claims 28
• 230000003993 interaction Effects 0.000 claims 27
• 239000000758 substrate Substances 0.000 claims 22
• 230000027455 binding Effects 0.000 claims 21
• 125000000524 functional group Chemical group 0.000 claims 16
• 239000002086 nanomaterial Substances 0.000 claims 14
• 239000002773 nucleotide Substances 0.000 claims 7
• 125000003729 nucleotide group Chemical group 0.000 claims 7
• 239000002245 particle Substances 0.000 claims 6
• 230000002776 aggregation Effects 0.000 claims 4
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 2
• 238000005054 agglomeration Methods 0.000 claims 2
• 230000004520 agglutination Effects 0.000 claims 2
• 238000004220 aggregation Methods 0.000 claims 2
• 239000002131 composite material Substances 0.000 claims 2
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 2
• 229910052737 gold Inorganic materials 0.000 claims 2
• 239000010931 gold Substances 0.000 claims 2
• 229910052709 silver Inorganic materials 0.000 claims 2
• 239000004332 silver Substances 0.000 claims 2
• 239000007787 solid Substances 0.000 claims 2
• 230000015572 biosynthetic process Effects 0.000 claims 1
• 230000015271 coagulation Effects 0.000 claims 1
• 238000005345 coagulation Methods 0.000 claims 1
• 230000009918 complex formation Effects 0.000 claims 1
• 238000001514 detection method Methods 0.000 claims 1
• 238000000502 dialysis Methods 0.000 claims 1
• 230000008014 freezing Effects 0.000 claims 1
• 238000007710 freezing Methods 0.000 claims 1
• 238000010438 heat treatment Methods 0.000 claims 1
• 230000003287 optical effect Effects 0.000 claims 1
• 238000010257 thawing Methods 0.000 claims 1